首页> 外文期刊>BioProcess International >Planning for Commercial Scale of Cell Therapy and Regenerative Medicine Products, Part 1:Achieving Manufacturability and Managing Cost of Goods
【24h】

Planning for Commercial Scale of Cell Therapy and Regenerative Medicine Products, Part 1:Achieving Manufacturability and Managing Cost of Goods

机译:规划细胞疗法和再生医学产品的商业规模,第1部分:实现可制造性和管理商品成本

获取原文
获取原文并翻译 | 示例
           

摘要

Much mystique and mystery surround the emerging industries of cell therapy and regenerative medicine. As companies progress toward commercial manufacture with potential game changers (e.g., cures for cancer and diabetes) the industry could be on the verge of significant breakthroughs. However, with no real successes to date, the question is raised: What core attributes are required to achieve commercial success? The tale of Dendreon's struggles highlights how difficult it can be to commercialize evenan approved cell therapy product.
机译:围绕细胞疗法和再生医学的新兴产业存在着许多神秘色彩。随着公司朝着具有潜在游戏规则改变者(例如,治疗癌症和糖尿病的方法)的商业化方向发展,该行业可能正处于重大突破的边缘。但是,迄今为止还没有真正的成功,所以提出了一个问题:要取得商业上的成功需要哪些核心属性? Dendreon奋斗的故事凸显了将批准的细胞疗法产品商业化的难度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号